i 3.00 Hours

Course Overview

The number of transplants performed annually increased each year from 2012 to 2016. There were 33,611 solid organ transplants performed in the United States in 2016. In addition to higher rates of transplantation, one-year allograft survival has significantly improved due to advances in clinical management of solid organ transplant patients and improved immunosuppressive therapy. Adequate immunosuppression is key to patient survival. Without effective immunosuppression after transplants, the allograft would face rejection and solid organ transplant recipients would only survive weeks at the most.

Immunosuppressive therapy is divided into two phases: induction therapy and maintenance therapy. Patients are often treated with induction therapy soon after the transplant with either a lymphocyte-depleting agent or an interleukin 2 receptor antagonist to prevent acute rejection. Maintenance therapy is then given for the entirety of the recipient’s life and usually involves a calcineurin inhibitor, a mycophenolate product, and/or corticosteroids. In addition, some newer immunosuppressive agents have been shown to limit toxicities experienced by solid organ transplant recipients, while still preventing allograft rejection.

Despite the efficacy of immunosuppression agents for allograft and patient survival, they pose numerous risks to patients due to infusion reactions, side effect profiles, and effects of long-term immunosuppression. Each immunosuppressive agent requires specific monitoring parameters to prevent and control toxicities and ensure adequate immunosuppression. Pharmacists play a major role in the care provided to solid organ transplant recipients and can improve long-term patient outcomes by preventing drug interactions, performing therapeutic drug monitoring, and educating patients about side effects and complications of immunosuppressive agents.

About the Course Author

Brittani Zurek, PharmD, is a pharmacist and medical writer who graduated from the University at Buffalo School of Pharmacy. Brittani Zurek, PharmD has declared that no conflict of interest, Relevant Financial Relationship or Relevant Non-Financial Relationship exists.

Get started now and your first course is free!

Become a member today and enjoy instant savings on all courses

Accreditation Information

Certificates provided by accrediting body (1 Match)

  • Accreditation Council for Pharmacy Education


    In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Type Activity: Knowledge Target Audience Designation: P ACPE Universal Activity Number: JA4008266-0000-21-242-H01-P

Course Details
  • Course Code:

  • Hours:

  • Type:

    Online Course
  • Release Date:

  • Expiration Date:

  • Learning Objectives:

    Describe types of graft rejection.; Identify the mechanisms of action and side effects for immunosuppressive medications used post-transplant.; List vaccination recommendations for post-transplant patients.; Recognize long-term complications of immunosuppression therapy.; Review matching procedures for donor and recipient prior to a transplant.
  • Target Audience:

    The target audience for this course is: Nurses; Pharmacists; in the following settings: Acute Care Facility.
  • Course Delivery Method and Format:

    Asynchronous/Online Distance Learning; please see certificate details for specifics on delivery format.
    Relias has a grievance policy in place to facilitate reports of dissatisfaction. Relias will make every effort to resolve each grievance in a mutually satisfactory manner. In order to report a complaint or grievance please contact Relias.
    If you require special accommodations to complete this module, please contact Relias Support by completing the web form (https://www.relias.com/help) or by using the chat functionality.
    All courses offered by Relias, LLC are developed from a foundation of diversity, inclusiveness, and a multicultural perspective. Knowledge, values and awareness related to cultural competency are infused throughout the course content.
    Reference herein to any specific commercial product, process, or service by trade name, trademark, service mark, manufacturer or otherwise does not constitute or imply any endorsement, recommendation, or favoring of, or affiliation with, Relias, LLC.
    All characteristics and organizations referenced in the following training are fictional. Any resemblance to any actual organizations or persons living or dead, is purely coincidental.
    To earn continuing education credit for this course you must achieve a passing score of 80% on the post-test and complete the course evaluation.
  • Accommodations:

    If you require special accommodations to complete this module, please contact Relias Customer Support here.
  • Disclosures:

    Expert Reviewers, Instructors, and Staff Writers disclosures will be listed above after the individuals' biographical paragraph. All other members involved within the planning of this educational activity have declared no conflict of interest exists when planning and developing this course.